{"nctId":"NCT00878826","briefTitle":"Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.","startDateStruct":{"date":"2009-05"},"conditions":["Venous Thrombosis"],"count":11,"armGroups":[{"label":"Enoxaparin 40 mg per day","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enoxaparin"]},{"label":"Enoxaparin 1 mg per kg daily","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enoxaparin"]},{"label":"Pre prescribed regimen of Enoxaparin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enoxaparin"]}],"interventions":[{"name":"Enoxaparin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. \\>18 years of age\n2. Warrants prophylaxis against venous thromboembolism in pregnancy according to American College of\n\nObstetrics and Gynecology Practice Bulletin 2000, reaffirmed in 2008:\n\n* history of idiopathic thrombosis\n* history of thrombosis related to pregnancy or oral contraceptive use\n* history of thrombosis accompanied by an underlying thrombophilia other than homozygous for the factor V Leiden mutation, heterozygous for both the factor V Leiden and the prothrombin G20210A mutation, or AT-III deficiency\n* without a history of thrombosis but who have an underlying thrombophilia and a strong family history of thrombosis\n* Known thrombophilia except for those listed above, with a history of adverse pregnancy outcome (APO) as defined by: ¡Ý3 pregnancy losses in the 1st trimester, ¡Ý2 pregnancy losses/stillbirth in 2nd trimester, ¡Ý1 pregnancy loss/intrauterine fetal demise (IUFD) in the 3rd trimester, intrauterine growth restriction (IUGR), abruptio placentae, or severe pre-Eclampsia prior to 34 weeks gestation.\n\nExclusion Criteria:\n\n1. Need for therapeutic-level anticoagulation as determined by physician\n2. Renal disease as defined by serum creatinine \\>1.0\n3. Weight \\>90kg\n4. Allergy to enoxaparin","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Peak Anti-Xa Level","description":"Goal peak anti-Xa level is 0.2 to 0.4 u/ml. We compared peak drug levels between different dosing arms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":"0.07"},{"groupId":"OG001","value":"0.46","spread":"0.27"},{"groupId":"OG002","value":"0.57","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.1"},{"groupId":"OG001","value":"0.34","spread":"0.23"},{"groupId":"OG002","value":"0.34","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0"},{"groupId":"OG001","value":"0.55","spread":"0.23"},{"groupId":"OG002","value":"0.56","spread":"0.07"}]}]}]},{"type":"SECONDARY","title":"Thromboembolic Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Bleeding Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Side Effect - Bruising","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":3},"commonTop":[]}}}